Clinical trials: Assessment Time
- Condition Assessment Time
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer's Disease
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease…
- Trial name
- NCT00499200
- Testing
- SRA-444
- Where
- Sweden
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Extraterrestrial Habitation Systems, Lunar Surface Habitation
A Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian Surface
This study evaluates the operational, environmental, and habitation-system requirements for sustained human presence on the lunar surface, the performance of the Lunar Gateway as a transit and staging architecture, and the…
- Conditions
- Extraterrestrial Habitation Systems, Lunar Surface Habitation, Lunar Water-Ice Resource Assessment, In-Situ Resource Utilization (ISRU)
- Trial name
- LUMEN-HAB (NCT07546461)
- Testing
- Habitat Systems Evaluation, Water-Ice Resource Utilization Assessment, EVA and Mobility Operations
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)
The purpose of the study is to evaluate the ability of injections Ji Gami(TM) to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451073
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Healthy Volunteers
Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4 (CYP3A4) substrate, in healthy…
- Trial name
- NCT04545944
- Testing
- Vonoprazan, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine.
- Trial name
- NCT01461993
- Testing
- rLP2086 and Gardasil, rLP2086, Gardasil
- Where
- 87 sites in United States
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers
- Trial name
- NCT04870164
- Testing
- Ensovibep
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Molecular Partners AG
Obstetric Labour, Premature, Premature Ejaculation
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.
- Trial name
- NCT00549211
- Testing
- GSK557296
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Phase 1, Single Dose
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single inhaled doses of PF-05212372.
- Conditions
- Phase 1, Single Dose, Safety, Toleration
- Trial name
- NCT01415102
- Testing
- PF-05212372
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
This study described in the present protocol consists of two sections. Part A is the first administration into man to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK1144814.
- Trial name
- NCT01381419
- Testing
- GSK1144814
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans.
- Trial name
- NCT06681181
- Testing
- GSK4528287
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
The purpose of this study in healthy people is to investigate safety, toleration and time course of plasma concentration of PF-04895162, following multiple oral doses for 14 days.
- Trial name
- NCT01691274
- Testing
- PF-04895162
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infection
A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744
This study is a Phase I single and repeat dose escalation study of GSK1265744 in healthy subjects and a single repeat dose cohort in HIV-1 infected subjects. The study is planned to consist of three parts.
- Trial name
- NCT00659191
- Testing
- GSK1265744
- Where
- 5 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Three Times Daily Dosing of UT-15C
To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers
- Trial name
- NCT01746485
- Testing
- UT-15C
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Obesity
A First-Time-In-Human Study in Healthy Subjects
This is a first-time-in-human study. The overall purpose of the study is to assess whether the drug is safe and well tolerated after single, increasing doses.
- Trial name
- FTIH (NCT00857883)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of…
- Trial name
- NCT04630067
- Testing
- AZD3427
- Where
- 10 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
- Trial name
- NCT00244543
- Testing
- R89674 (generic name not yet established)
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Fertility
TiLE (Time Lapse Eeva) Clinical Trial
The purpose of the study was to explore the added value of adjunctive use of Early Embryo Viability Assessment (Eeva) with morphological grading in identifying optimal embryos for transfer.
- Trial name
- TiLE (NCT02417441)
- Testing
- Eeva
- Where
- 23 sites in Canada, Denmark and 7 more
- Volunteers
- 976 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
- Trial name
- NCT04161482
- Testing
- Furosemide 80 mg (8 mg/mL)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- scPharmaceuticals, Inc.
Healthy
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
- Trial name
- NCT01120418
- Testing
- Besifloxacin Ophthalmic Suspension 0.6%
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated